AGENUS Business Summary

Agenus Inc. (AGEN) is a clinical-stage immuno-oncology firm that generates revenue through strategic partnerships, licensing fees, and non-cash royalties from its QS-21 adjuvant platform, supplemented by a newly implemented fee-for-service biologics manufacturing model. The company’s business is segmented into three primary pillars: proprietary immuno-modulatory antibodies (notably the botensilimab and balstilimab combination), adoptive cell therapies via its subsidiary MiNK Therapeutics, and vaccine adjuvants through SaponiQx. In 2026, Agenus has pivoted toward monetizing "authorized access" programs in Europe to provide early-stage revenue while advancing its late-stage pipeline toward regulatory submission. It competes directly with Iovance Biotherapeutics, Moderna, and ImmunityBio, distinguishing itself as a niche leader in treating "immunologically cold" tumors, such as microsatellite stable (MSS) colorectal cancer, which are largely unresponsive to existing PD-1 therapies. Agenus was co-founded in 1994 by Dr. Garo H. Armen and Dr. Pramod K. Srivastava. Dr. Armen, the current Chairman, CEO, and interim CFO, possesses a distinguished background in both science and finance, having previously served as Chairman of Elan Corporation and as a senior analyst at EF Hutton. The executive suite includes President and COO Dr. Jennifer Buell, who leads corporate strategy and clinical operations, and Chief Medical Affairs Officer Dr. José Iglesias, an industry veteran with experience at Amgen and BeiGene who oversees global clinical readiness. The company’s board and investor roster feature prominent names such as Tom Harrison and major institutional holders like BlackRock and Vanguard, alongside strategic partner Zydus Lifesciences, which recently provided $141 million in capital to support the company’s pivotal Phase 3 BATMAN trial and U.S. manufacturing readiness.